Medullary Thyroid Cancer With Undetectable Serum Calcitonin

被引:37
|
作者
Brutsaert, Erika F. [1 ]
Gersten, Adam J. [2 ]
Tassler, Andrew B. [3 ]
Surks, Martin I. [1 ]
机构
[1] Montefiore Med Ctr, Dept Med, Div Endocrinol, Bronx, NY 10467 USA
[2] Montefiore Med Ctr, Dept Pathol, Bronx, NY 10467 USA
[3] Montefiore Med Ctr, Dept Otorhinolaryngol, Bronx, NY 10467 USA
关键词
GENE-RELATED PEPTIDE; CARCINOEMBRYONIC ANTIGEN; FOLLOW-UP; PROGNOSTIC-FACTORS; CARCINOMA; PROCALCITONIN; DIAGNOSIS; SURVEILLANCE; SERIES; MARKER;
D O I
10.1210/jc.2014-3095
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Calcitonin is a sensitive biomarker that is used for diagnosis and follow-up in medullary thyroid cancer (MTC). In patients with tumors > 1 cm, it is uncommon for preoperative serum calcitonin to be in the normal laboratory reference range in patients with MTC, and even more unusual for serum calcitonin to be undetectable. The Case: A 39-year-old woman was found to have a left thyroid nodule on magnetic resonance imaging done for neck pain. Ultrasound and fine-needle aspiration biopsy were performed, and cytopathology was positive for malignant cells. The cells also had features suggestive of a neuroendocrine tumor, and the specimen was immune-stained with calcitonin. There was positive immunoreactivity for calcitonin in isolated cells of the cytospin, highly favoring a diagnosis of MTC. Serum calcitonin was < 2 pg/mL (< 6 pg/mL), and serum carcinoembryonic antigen was 3.1 ng/mL (<5.2 ng/mL). Given the low calcitonin levels, procalcitonin was also tested and was elevated at 0.21 ng/mL (<0.1 ng/mL). The patient subsequently underwent a total thyroidectomy and central and ipsilateral lateral lymph node dissection. Histopathology confirmed a 2.6 x 2.0 x 1.2-cm MTC, with strong, diffuse immunostaining for calcitonin. Postoperatively, serum calcitonin has remained undetectable, carcinoembryonic antigen has remained within the reference range, and procalcitonin has become undetectable. Conclusions: We present a rare case of a patient with MTC with undetectable preoperative serum calcitonin, whose tumor demonstrated strong, diffuse immunohistochemical staining for calcitonin. We discuss the possible pathogenesis of calcitonin-negative MTC and the challenges in following patients with this condition.
引用
收藏
页码:337 / 341
页数:5
相关论文
共 50 条
  • [21] Management of medullary thyroid cancer
    Ball, D. W.
    MINERVA ENDOCRINOLOGICA, 2011, 36 (01) : 87 - 98
  • [22] Management of Medullary Thyroid Cancer
    Viola, David
    Elisei, Rossella
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2019, 48 (01) : 285 - +
  • [23] Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer
    Elisei, Rossella
    Lorusso, Loredana
    Piaggi, Paolo
    Torregrossa, Liborio
    Pellegrini, Giovanni
    Molinaro, Eleonora
    Agate, Laura
    Bottici, Valeria
    Pani, Fabiana
    Insilla, Andrea Cacciato
    Casella, Francesca
    Ciampi, Raffaele
    Tognetti, Ilaria
    Materazzi, Gabriele
    Basolo, Fulvio
    Romei, Cristina
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 173 (03) : 297 - 304
  • [24] Basal and Stimulated Calcitonin and Procalcitonin by Various Assays in Patients with and without Medullary Thyroid Cancer
    Kratzsch, Juergen
    Petzold, Anne
    Raue, Friedhelm
    Reinhardt, Walter
    Broecker-Preuss, Martina
    Goerges, Rainer
    Mann, Klaus
    Karges, Wolfram
    Morgenthaler, Nils
    Luster, Markus
    Reiners, Christoph
    Thiery, Joachim
    Dralle, Henning
    Fuhrer, Dagmar
    CLINICAL CHEMISTRY, 2011, 57 (03) : 467 - 474
  • [25] Calcitonin and complementary biomarkers in the diagnosis of hereditary medullary thyroid carcinoma in children and adolescents
    Eckelt, Felix
    Pfaeffle, Roland
    Kiess, Wieland
    Kratzsch, Juergen
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2021, 34 (12) : 1491 - 1504
  • [26] Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays?
    Niederle, Martin B.
    Scheuba, Christian
    Riss, Philipp
    Selberherr, Andreas
    Koperek, Oskar
    Niederle, Bruno
    THYROID, 2020, 30 (07) : 974 - 984
  • [27] Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center
    Kim, Sun Jung
    Yun, Hyeok Jun
    Shin, Su-Jin
    Lee, Yong Sang
    Chang, Hang-Seok
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [28] Incidental medullary thyroid microcarcinoma revealed by mild increase of preoperative serum calcitonin levels: therapeutic implications
    Boschin, Isabella Merante
    Torresan, Francesca
    Toniato, Antonio
    Zane, Mariangela
    Ide, Eric Casal
    Pennelli, Gianmaria
    Rampin, Lucia
    Colletti, Patrick M.
    Rubello, Domenico
    Pelizzo, Maria Rosa
    ENDOCRINE, 2014, 45 (03) : 448 - 453
  • [29] Clinical outcomes of patients with hypercalcitoninemia after initial treatment for medullary thyroid cancer and postoperative serum calcitonin cutoffs for predicting structural recurrence
    Cho, Yoon Young
    Jang, Hye Won
    Jang, Ju Young
    Kim, Tae Hyuk
    Choe, Jun-Ho
    Kim, Jung-Han
    Kim, Jee Soo
    Kim, Sun Wook
    Chung, Jae Hoon
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 (10): : 1501 - 1508
  • [30] Pretargeted Radioimmunotherapy in Rapidly Progressing, Metastatic, Medullary Thyroid Cancer
    Kraeber-Bodere, Francoise
    Salaun, Pierre-Yves
    Oudoux, Aurore
    Goldenberg, David M.
    Chatal, Jean-Francois
    Barbet, Jacques
    CANCER, 2010, 116 (04) : 1118 - 1125